Screening Impact of Anti-HDV Reflex Testing Among HBsAg-Positive Individuals
Journal of Clinical Medicine · 22.05.2026 · 15 (11) · 4019
DOI: 10.3390/jcm15114019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 22.05.2026. Verfasst von Tor Regev-Sadeh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3525433, Israel. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Hepatitis D virus (HDV) causes one of the most severe forms of chronic viral hepatitis. Despite its severity, universal screening of hepatitis B surface antigen (HBsAg)-positive individuals, as recommended by European guidelines, is not widely implemented. This study aimed to evaluate the yield of reflex HDV testing and to characterize HBV carriers who tested positive or negative for anti-HDV.
Methods
A retrospective cohort study was conducted using the Clalit Health Services database in northern Israel (2014–2024). HBsAg-positive patients were categorized into two groups: those screened for HDV via reflex testing (2019–2024) and those tested based on clinical discretion (2014–2019). We compared these cohorts to evaluate the impact of reflex screening on coverage, diagnostic yield, and time to diagnosis.
Results
Among 1336 HBsAg-positive individuals, HDV screening rates increased from 57.5% to 93.1% following reflex implementation. HDV seropositivity increased from 3.17% to 6.48% (p = 0.02). Ethiopian-born individuals had significantly higher positivity than others (10.4% vs. 3.9%, p = 0.0221). The average time from HBV diagnosis to HDV testing decreased from 38.1 ± 31 months (median 37.5) to 1.3 ± 6.1 months (median 0).
Conclusions
Anti-HDV reflex testing significantly improved screening coverage, increased detection of anti-HDV seropositive cases and was associated with shorter time to serologic identification. These findings support the integration of reflex testing into national screening policies to enable earlier diagnosis and reduce the burden of infection.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3525433, Israel.
- Department of Radiology, Emek Medical Center, Afula 1834111, Israel.
- Emek Medical Center Laboratories, Clalit Health Services, Afula 1834111, Israel.
- Department of Gastroenterology and Hepatology, Hillel Yaffe Medical Center, Hadera 38100, Israel.
- Liver Unit, Rambam Health Care Campus, Haifa 3109601, Israel.
- Department of Gastroenterology, Rambam Health Care Campus, Haifa 3109601, Israel.
ORCID-Profile: Tor Regev-Sadeh, Ziv Neeman, Mifleh Tatour, Rawi Hazzan
Zitieren
APA
Regev-Sadeh, T., Neeman, Z., Schwartz, N., Rozenberg, O., Abu Baker, F., Saadi, T., Tatour, M., & Hazzan, R. (2026). Screening Impact of Anti-HDV Reflex Testing Among HBsAg-Positive Individuals. Journal of Clinical Medicine, 15(11), 4019. https://doi.org/10.3390/jcm15114019
Vancouver
Regev-Sadeh T, Neeman Z, Schwartz N, Rozenberg O, Abu Baker F, Saadi T, et al. Screening Impact of Anti-HDV Reflex Testing Among HBsAg-Positive Individuals. Journal of Clinical Medicine. 2026;15(11):4019. doi:10.3390/jcm15114019
BibTeX
@article{RegevSadeh2026,
author = {Regev-Sadeh, Tor and Neeman, Ziv and Schwartz, Naama and Rozenberg, Orit and Abu Baker, Fadi and Saadi, Tarek and Tatour, Mifleh and Hazzan, Rawi},
title = {Screening Impact of Anti-HDV Reflex Testing Among HBsAg-Positive Individuals},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {11},
pages = {4019},
doi = {10.3390/jcm15114019}
}
EUVIMED